U.S. markets close in 5 hours 38 minutes
  • S&P 500

    4,384.83
    -2.33 (-0.05%)
     
  • Dow 30

    34,840.01
    +1.85 (+0.01%)
     
  • Nasdaq

    14,625.65
    -55.42 (-0.38%)
     
  • Russell 2000

    2,195.35
    -20.15 (-0.91%)
     
  • Crude Oil

    70.00
    -1.26 (-1.77%)
     
  • Gold

    1,815.60
    -6.60 (-0.36%)
     
  • Silver

    25.53
    -0.04 (-0.16%)
     
  • EUR/USD

    1.1871
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.1610
    -0.0130 (-1.11%)
     
  • GBP/USD

    1.3901
    +0.0017 (+0.13%)
     
  • USD/JPY

    108.9390
    -0.3700 (-0.34%)
     
  • BTC-USD

    38,505.73
    -1,140.27 (-2.88%)
     
  • CMC Crypto 200

    939.70
    -3.74 (-0.40%)
     
  • FTSE 100

    7,089.51
    +7.79 (+0.11%)
     
  • Nikkei 225

    27,641.83
    -139.19 (-0.50%)
     

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S - ORPH

·2 min read

NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)
Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

The investigation concerns whether Orphazyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On or around September 29, 2020, Orphazyme conducted its initial public offering ("IPO"), issuing 7.6 million American depositary shares ("ADSs") priced at $11.00 per share. Then, on May 7, 2021, Orphazyme issued a press release "announc[ing] topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerisos (ALS)". The press release disclosed that the Company's "ORARIALS-01 pivotal trial . . . did not meet its primary and secondary endpoints to show benefit in people living with ALS."

On this news, Orphazyme's ADS price fell $2.81 per ADS, or 32.83%, to close at $5.75 per ADS on May 7, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-orphazyme-as----orph-301293189.html

SOURCE Pomerantz LLP